(Q37483910)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Pharmacotherapy of vasculitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

Raashid Ahmed Luqmani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Marian Chan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1273-1289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

EULAR recommendations for the management of large vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

EULAR recommendations for the management of primary small and medium vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Polymyalgia rheumatica and giant-cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Steroid management in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Experience with infliximab (anti-TNF monoclonal antibody) as monotherapy for giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Successful treatment of resistant giant cell arteritis with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Treatment of refractory temporal arteritis with adalimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

A case of polyarteritis nodosa successfully treated by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Drug targets in hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Reversal of Impaired Splenic Function in Patients with Nephritis or Vasculitis (or Both) by Plasma Exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Nationwide survey of Kawasaki disease and acute rheumatic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Evaluation of the Efficacy of Treatment of Kawasaki Disease before Day 5 of Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Kawasaki disease in infants less than one year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Ulinastatin therapy in kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

The effect of TNFalpha blockade in complicated, refractory Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Infliximab treatment for refractory Kawasaki syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Longstanding Obliterative Panarteritis in Kawasaki Disease: Lack of Cyclosporin A Effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Clinical uses of intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Epidemiology of Schönlein-Henoch Purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Henoch-Schönlein Purpura in adults: outcome and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946401

10.1517/14656560902946401

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19445559%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference